BioSpace News Archive

A dual listing will provide increased awareness of Abacus in the public markets, access to a large new pool of potential investors and also enhance liquidity.

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets

Respected thought leader on chronic pain and appropriate treatment modalities joins industry leading digital pain recovery platform, SimpleTherapy, as advisory board member.

Dr. Kerstein is a global expert on the use and application of the T-Scan™ digital occlusal analysis system, and a pioneer and academic science advocate for digital occlusal technology.

Perrigo Company plc (NYSE; TASE: PRGO) today announced the successful completion of its acquisition of Ranir Global Holdings LLC (“Ranir”), the leading global store brand supplier of oral self-care products, for $750 million in cash.

UCB and DEARhealth collaborate on new software to improve patient care

Ora®, Inc. (“Ora”) announced that it and its affiliate, OIG LLC (“OIG”), have entered into a partnership with InFocus Capital Partners LLC. Ora is committed to supporting early, mid, and late stage companies in strategy, nonclinical, regulatory, and clinical development.

Asieris MediTech Co, Ltd, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, and Photocure ASA, The Bladder Cancer Company, announced that they have entered into a License Agreement for world-wide development and commercialization of Cevira® for the treatment of HPV induced cervical precancerous lesions.

SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Troy Cox joined its Board of Directors, effective immediately. Mr. Cox, who previously held the position of Chief Executive Officer of Foundation Medicine, brings extensive knowledge of the biopharmaceutical industry to SOPHiA GENETICS.

Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the prescription drug products and lots, within expiry, distributed during the time period as indicated in the tables below.